BUZZ-Medicus Pharma gains after cutting royalty payment to Teverelix
Reuters
Jan 22
BUZZ-<a href="https://laohu8.com/S/MDCX">Medicus Pharma</a> gains after cutting royalty payment to Teverelix
** Shares of drug developer Medicus PharmaMDCX.O rise 12% to $1.49 premarket
** Co says it has cut royalty payments on investigational prostate cancer drug teverelix to 2% from ~4% after amending its deal with UK research group LifeArc
** Co's teverelix is being tested for advanced prostate cancer and recurring acute urinary retention, a condition where men suddenly cannot urinate
** Co says early studies showed teverelix quickly lowers hormone levels key to prostate cancer treatment
** MDCX plans mid‑stage testing before seeking commercial partners; also expects early‑2026 data for its SkinJect skin cancer patch, per co
** Shares down ~37% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.